Canterbury DHB


Further Reading

  1. Cazzola M (2016). Introduction to a review series: the 2016 revision of the WHO classification of tumors of hematopoietic and lymphoid tissues Blood 2016 127:2361-2364; doi:
  2. Arber DA, et al. (2016). The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood First Edition paper, April 11, 2016; DOI 10.1182.
  3. Larsen RA (2015). Is there a best TKI for chronic phase CML? Blood 2015 126:2370-2375.
  4. London Cancer CML Guidelines 2015-16v1.0
  5. Baccarani M, et al. (2013). European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013 122:872-884; doi:
  6. Hochhaus A, et al. (2017). Chronic Myeloid Leukamia – ESMO Clinical Practice Guidelines. Ann Oncol (2017) 28 (suppl 4): iv41–iv51.
  7. Soverini S, et al. (2011). BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood First Edition paper, May 11, 2011; DOI 10.1182.
  8. Steegmann JL, et al. (2016). European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016;30(8):1648-1671. doi:10.1038/leu.2016.104.
  9. Aghel N, et al. (2017). Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance. Vasc Health Risk Manag. 2017 Aug 4; 13: 293–303.
  10. Hughes TP, Ross DM (2016). Moving treatment-free remission into mainstream clinical practice in CML. Blood 2016 128:17-23; doi:
  11. Guilhot F (2016). Cytogenetics in CML: more important than you think. Blood 2016 127:2661-2662.
  12. Baccarani M, et al. (2012). Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 23 Suppl 7: vii72-77.
  13. Cortes J, et al. (2009). How I treat newly diagnosed chronic phase CML. Blood 2012 120:1390.
  14. Cortes JE, et al. (2016). Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. Journal of Clinical Oncology. 2016 Jul;34(20):2333-40.
  15. Hochhaus A, et al. (2017). Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med. 2017;376(10):917
  16. Hochhaus A, et al. (2017). Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia 2017; 31: 1525–1531. 40.
  17. Hughes TP, Ross DM (2016). Moving treatment-free remission into mainstream clinical practice in CML. Blood 2016; 128: 17–23. 41.
  18. Kantarjian H, Cortes J (2011). Considerations in the management of patients with Philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy. Journal of Clinical Oncology 29(12): 1512-1516.
  19. Mahon FX, et al. (2010). Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11: 1029–1035.39.
  20. Marin D (2012). Initial choice of therapy among plenty for newly diagnosed chronic myeloid leukemia. Hematology Am Soc Hematol Educ Program 2012: 115-121.
  21. O’Brien SG, et al. IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348(11):994-1004.
  22. Rea D, et al. (2012). First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia. Leukemia 26(10): 2254-2259.
  23. Ross DM, et al. (2006). Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL. Leukemia 2006;20(4):664-670.
  24. Rousselot P, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol 2014;32(5):424-430.
  25. Saußele S, et al. (2016). The concept of treatment-free remission in chronic myeloid leukemia. Leukemia.2016; 30: 1638–1647.
  26. Shami PJ, Deininger M (2012). Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy. Leukemia 26(2): 214-224.
  27. Steegmann JL, et al. (2016). European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia 2016; 30: 1648–1671.
  28. Yeung DT, et al. (2015).TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. Blood. 2015 Feb;125(6):915-23. Epub 2014 Dec 17

About this Canterbury DHB document (533108):

Document Owner:

Bridgett McDiarmid (see Who's Who)

Last Reviewed:

August 2018

Next Review:

April 2021


Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 533108